SCHEMBL5385220

SCHEMBL5385220

CCCCCCCCCCCCCOc1ccc(NS(=O)(=O)CCCC)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.70
RAB9A P51151 1/20 0.70
AR P10275 1/20 0.67
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA4 P22748 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
LMNA P02545 2/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
NR5A1 Q13285 1/20 0.50
ADRB2 P07550 1/20 0.49
ADRB1 P08588 1/20 0.49
ADRB3 P13945 1/20 0.49
S1PR1 P21453 1/20 0.49
S1PR3 Q99500 1/20 0.49
FAAH O00519 7/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11431936 0.93 NPC1 (0.64) NPC1RAB9AARCA12CA1
SCHEMBL3563414 0.84 AR (0.62) NPC1RAB9AARCA12CA1
SCHEMBL7263640 0.81 NPC1 (0.74) NPC1RAB9ACA12CA1CA2
SCHEMBL5385213 0.80 AR (0.54) NPC1RAB9AARCA12CA1
SCHEMBL25788194 0.79 NPC1 (0.67) NPC1RAB9ALMNASMN1; SMN2NR5A1
SCHEMBL14113144 0.79 NPC1 (0.93) NPC1RAB9AARCA12CA1
SCHEMBL11431934 0.78 AR (0.52) NPC1RAB9AARCA12CA1
SCHEMBL3555020 0.78 AR (0.61) NPC1RAB9AARCA12CA1
SCHEMBL27812662 0.78 AR (0.71) NPC1RAB9AARLMNAHPGD
SCHEMBL13763467 0.78 HPGD (0.56) NPC1RAB9AARCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312337-B2 Oxadiazoles and their manufacture EASTMAN KODAK COMPANY (US) 2007-12-25 US claimed
US-7268235-B2 Method for preparation of N-pyrazolylamidoximes EASTMAN KODAK COMPANY (US) 2007-09-11 US claimed
US-20060074245-A1 Method for preparation of N-pyrazolylamidoximes EASTMAN KODAK COMPANY 2006-04-06 US claimed
US-20060069262-A1 Oxadiazoles and their manufacture EASTMAN KODAK COMPANY 2006-03-30 US claimed
US-6657083-B2 Photographic couplers; acylation amine group in position 2 EASTMAN KODAK COMPANY 2003-12-02 US claimed
US-6613943-B2 Intermediates for 4-substituted-2,5-diaminophenol derivatives as phenolic cyan couplers for color photography; deblocking the 2-acyl group by hydrolysis EASTMAN KODAK COMPANY 2003-09-02 US claimed
US-20030109716-A1 5-ACYLAMINO-2-AMINO-4-SUBSTITUTED-PHENOL COMPOUNDS AND METHOD OF USING THEM EASTMAN KODAK COMPANY 2003-06-12 US claimed
US-20030109753-A1 4-acylamino-2-hydroxy-5-substituted-acylanilide compounds and method of using them EASTMAN KODAK COMPANY 2003-06-12 US claimed
US-6525219-B1 Chemical intermediates for cyan dye forming couplers; deblocking, hydrolysis, acylation EASTMAN KODAK COMPANY 2003-02-25 US claimed
US-6476202-B1 5-acylamino-2-arylazo, nitro, or nitroso-4-substituted-phenol compounds and method of using them EASTMAN KODAK COMPANY 2002-11-05 US claimed
US-4840883-A STORAGE STABILITY KONICA CORPORATION (JP) 1989-06-20 US claimed
EP-0296780-A2 Light-sensitive silver halide color photographic material containing novel cyan coupler KONICA CORPORATION (JP) 1988-12-28 EP claimed
US-7312337-B2 Oxadiazoles and their manufacture EASTMAN KODAK COMPANY (US) 2007-12-25 US disclosed
US-7268235-B2 Method for preparation of N-pyrazolylamidoximes EASTMAN KODAK COMPANY (US) 2007-09-11 US disclosed
US-20060074245-A1 Method for preparation of N-pyrazolylamidoximes EASTMAN KODAK COMPANY 2006-04-06 US disclosed
US-20060069262-A1 Oxadiazoles and their manufacture EASTMAN KODAK COMPANY 2006-03-30 US disclosed
US-6525219-B1 Chemical intermediates for cyan dye forming couplers; deblocking, hydrolysis, acylation EASTMAN KODAK COMPANY 2003-02-25 US disclosed
US-6482953-B1 2-benzyloxy-4-nitro-5-substituted-acylanilide compounds and method of using them EASTMAN KODAK COMPANY 2002-11-19 US disclosed
US-6482985-B1 2-benzyloxy-5-halo-acylanilide compounds and method of using them EASTMAN KODAK COMPANY 2002-11-19 US disclosed
US-4840883-A STORAGE STABILITY KONICA CORPORATION (JP) 1989-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109753-A1 4-acylamino-2-hydroxy-5-substituted-acylanilide compounds and method of using them CBR3, AADAC, HAAO NPC1 2847/4885RAB9A 1906/4885AR 234/4885
US-20030109716-A1 5-ACYLAMINO-2-AMINO-4-SUBSTITUTED-PHENOL COMPOUNDS AND METHOD OF USING THEM AADAT, AAAS, ANXA7 NPC1 4256/4885RAB9A 1371/4885AR 183/4885
US-20060069262-A1 Oxadiazoles and their manufacture OXA1L, CYP1B1, OXER1 NPC1 3914/4885RAB9A 4154/4885AR 889/4885
US-20060074245-A1 Method for preparation of N-pyrazolylamidoximes KCNH1, KCNJ2, KCNH2 NPC1 3178/4885RAB9A 3696/4885AR 4103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.